Sponsors

Messenger RNA: a basis for vaccine technology and cancer treatment

Recent media coverage has highlighted the relatively new technology involving mRNA that has found application in COVID vaccination, but also in the treatment of cancer. The mRNA technology works by sending instructions to cells to produce an antigen or protein, thus enabling the immune system to target cells for destruction. Here, Science Editor Brian Nation compiles a small selection of activity in this important research.

mRNA therapeutics in cancer immunotherapy

Beck JD, Reidenbach D, Salomon N et al. Mol Cancer. 2021 Apr 15; 20 (1): 69. doi: 10.1186/s12943-021-01348-0.

Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment or peptide and lends itself to a broad range of pharmaceutical applications, including different modalities of cancer immunotherapy. With the ease of rapid, large-scale Good Manufacturing Practice-grade mRNA production, mRNA is ideally poised not only for off-the-shelf cancer vaccines but also for personalised neoantigen vaccination. The ability to stimulate pattern recognition receptors and thus an anti-viral type of innate immune response equips mRNA-based vaccines with inherent adjuvanticity. 

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.

Latest Issues

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

Hyatt Regency, Vancouver, Canada
19-23 November, 2024

11th Digital Pathology & AI Congress: Europe

Hilton London Metropole, 255 Edgware Road, London, W2 1JU
11-12 December, 2024

Microbiology Society Annual Conference 2025

Liverpool Arena and Convention Centre
31 March - 3 April, 2025

BSMT Annual Microbiology Conference

RAF Museum, Hendon, London NW9 5LL
15 May, 2025

Ghent Pathology 2025

ICC Ghent, Belgium
24-26 June, 2025